Serum metabolomics of small cell lung cancer patients based on UPLC-TOF/MS
10.11904/j.issn.1002-3070.2019.03.002
- VernacularTitle:基于UPLC-TOF/MS的小细胞肺癌患者血清代谢组学研究
- Author:
Jiawen ZHANG
1
;
Yan YU
;
Wei ZHANG
;
Jingyan CAO
;
Wen LUO
;
Lihua SHANG
Author Information
1. 哈尔滨医科大学附属第一医院呼吸内科(哈尔滨 150001)
- Keywords:
Small lung cancer;
Metabolites;
Biomarker;
UPLC-TOF/MS
- From:
Practical Oncology Journal
2019;33(3):200-205
- CountryChina
- Language:Chinese
-
Abstract:
Objective The objective of this study was to explore the differences of serum metabolomics between small cell lung cancer(SCLC)patients and healthy volunteers,and to discover serum potential biomarkers for identification and small cell lung cancer staging. Methods Ultra-performance liquid chromatography time of flight mass spectrometry(UPLS-TOF/MS)was used to establish the serum metabolic profile of SCLC. Principal Component Analysis(PCA)and orthogonal hidden variables were analyzed by the EZinfo2. 0 software. Orthogonal Partial Least Squares Discriminant Analysis(OPLS-DA)was used to analyze the metabolic differ-ences between the case and normal control groups. Through cluster analysis using HMDB and METLIN database to search for the exact mass-to-charge ratio of the difference,preliminary identification of some substances with significant differences was carried out. Results Ten differential metabolites such as lysophosphatidylcholine between patients and control groups were screened and identi-fied by mass spectrometry and database search. There were 10 different metabolites such as glycocholic acid in the contour analysis of SCLC patients with different stages. Conclusion There is a significant difference in serum metabolism between SCLC patients and healthy controls. The discovery of differential metabolites provides experimental evidence for the identification of small cell lung cancer and potential markers of staging.
